Near-sightedness

Dopavision Announces Topline Results in Clinical Trial of Targeted Photobiomodulation Approach for Progressive Myopia

Retrieved on:

tisdag, maj 28, 2024

Dopavision, a pioneering company dedicated to transforming pediatric eye care, today announced topline findings from its MyopiaX-1 proof-of-concept clinical trial (NCT04967287).

Key Points:

Dopavision, a pioneering company dedicated to transforming pediatric eye care, today announced topline findings from its MyopiaX-1 proof-of-concept clinical trial (NCT04967287).
MyopiaX delivers targeted photobiomodulation to the eye with the aim of managing the progression of myopia among children.
Over six months, treatment with MyopiaX shows signals of clinical effect on the rate of myopia progression.
MyopiaX was safe and tolerable over the six-month trial period, with no ocular safety events reported, validating MyopiaX as a low-risk, non-invasive approach.

STAAR Surgical Reports First Quarter 2024 Results

Retrieved on:

tisdag, maj 7, 2024

STAAR Surgical Company (NASDAQ: K), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today reported financial results for the first quarter ended March 29, 2024.

Key Points:

STAAR Surgical Company (NASDAQ: K), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today reported financial results for the first quarter ended March 29, 2024.
Gross profit margin for the first quarter of 2024 was 78.9% of net sales compared to the prior year quarter of 78.3% of net sales.
Product and country mix favorably impacted gross margin in the first quarter of 2024 as compared to the prior year quarter.
Operating expenses for the first quarter of 2024 were $63.3 million compared to the prior year quarter of $54.8 million.

STAAR Surgical Announces Milestone Strategic Agreement in U.S. with IQ Laser Vision

Retrieved on:

tisdag, maj 7, 2024

Optical, Health, Surgery, Medical Devices, Education, Near-sightedness, Left, Presbyopia, EVO, Refractive surgery, Cataract, PIB, STAAR, Surgeon, Nave, MD, Quality, ICL, Contact, Chairperson, Lens, ASCRS, Eye, Society, Athlete, Multimedia, Marketing, SMILE, Astigmatism, Growth, Telescopic sight

View the full release here: https://www.businesswire.com/news/home/20240507036972/en/

Key Points:

View the full release here: https://www.businesswire.com/news/home/20240507036972/en/
Tom Frinzi, Chair of the Board, President and CEO, STAAR Surgical (Left) and Dr. Robert T. Lin, founder and surgeon, IQ Laser Vision (Right).
(Photo: Business Wire)
IQ Laser Vision will make EVO ICL lenses a primary option for patients seeking surgical vision correction within the range of -3D to -20D, as part of its comprehensive refractive offering.
IQ Laser Vision intends to nearly double its volume in EVO ICLs over the course of the next 12 months.
Today, we’re thrilled to announce that IQ Laser Vision has joined our U.S. Highway 93 program with the largest agreement for EVO ICL in the U.S. thus far.

STAAR Surgical Strengthens Leadership Team with Appointments of Nancy Sabin as Chief Marketing Officer and Nathaniel Sisitsky as General Counsel

Retrieved on:

onsdag, maj 1, 2024

STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced Nancy Sabin has been named Chief Marketing Officer and Nathaniel Sisitsky has been named General Counsel.

Key Points:

STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced Nancy Sabin has been named Chief Marketing Officer and Nathaniel Sisitsky has been named General Counsel.
View the full release here: https://www.businesswire.com/news/home/20240501408389/en/
“We are thrilled to strengthen the STAAR team with the addition of Nancy and Nate, two seasoned executives with extensive senior leadership experience.
“Nancy is a perfect fit for the newly created Chief Marketing Officer position and will be critical to driving our brand awareness and innovation globally.
“I am thrilled to join the STAAR leadership team at a time of significant opportunity and growth for our vision correction lenses,” said Nate Sisitsky.

STAAR Surgical to Report First Quarter Results on May 7, 2024

Retrieved on:

måndag, april 29, 2024

Optical, Health, Surgery, Medical Devices, Near-sightedness, STAAR, Presbyopia, Astigmatism, Webcast, EVO

STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that it will release financial results for the first quarter ended March 29, 2024, on Tuesday, May 7, 2024, after the market close.

Key Points:

STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that it will release financial results for the first quarter ended March 29, 2024, on Tuesday, May 7, 2024, after the market close.
STAAR will host a conference call and webcast on Tuesday, May 7 at 4:15 p.m. Eastern / 1:15 p.m. Pacific to discuss its financial results and operational progress.
To access the conference call please dial 833-816-1164 for domestic participants and 412-317-1899 for international participants.
The live webcast can be accessed from the investor relations section of the STAAR website at www.staar.com .

PolyU forms global partnership with ZEISS Vision Care to expand impact and accelerate market penetration of patented myopia control technology

Retrieved on:

torsdag, april 25, 2024

Knowledge, Transfer, Education, School, Near-sightedness, ZEISS, IP, Hong Kong Polytechnic University, Knowledge transfer, Partnership, Research, Contact, Associate, Invention, Entrepreneurship, Telescopic sight

Under the terms of the agreement, ZEISS will adopt PolyU's patented myopia control technology in its specialised optical products.

Key Points:

Under the terms of the agreement, ZEISS will adopt PolyU's patented myopia control technology in its specialised optical products.
Furthermore, this partnership paves the way for a long-term collaboration in research and development between PolyU and ZEISS, focusing on myopia control and other ophthalmic technologies.
PolyU innovations in the areas of myopia control and other ophthalmic issues are poised to make unprecedented societal impact."
The partnership between PolyU and ZEISS Vision Care is expected to create further innovative solutions that will enhance vision preservation and improvement for people around the world.

PolyU forms global partnership with ZEISS Vision Care to expand impact and accelerate market penetration of patented myopia control technology

Retrieved on:

torsdag, april 25, 2024

Under the terms of the agreement, ZEISS will adopt PolyU's patented myopia control technology in its specialised optical products.

Key Points:

Under the terms of the agreement, ZEISS will adopt PolyU's patented myopia control technology in its specialised optical products.
Furthermore, this partnership paves the way for a long-term collaboration in research and development between PolyU and ZEISS, focusing on myopia control and other ophthalmic technologies.
PolyU innovations in the areas of myopia control and other ophthalmic issues are poised to make unprecedented societal impact."
The partnership between PolyU and ZEISS Vision Care is expected to create further innovative solutions that will enhance vision preservation and improvement for people around the world.

Stuart Therapeutics, Inc. Announces Upcoming Presentations at ARVO 2024

Retrieved on:

fredag, april 19, 2024

Near-sightedness, University, Retinitis pigmentosa, OIS, Generator, Poster, Research, Eye, Season, Annual general meeting, Therapy, ARVO

STUART, Fla., April 19, 2024 /PRNewswire/ -- Stuart Therapeutics, Inc., a clinical-stage ophthalmic biopharmaceutical company focused on developing therapies for the treatment of anterior segment, refractive and posterior segment eye disorders, today announced that the company will be presenting its latest research results at both the Association for Research in Vision and Ophthalmology annual meeting, and at two meetings sponsored by the Ophthalmology Innovation Source (OIS) in early May. Eric Schlumpf, Stuart Therapeutics' President and CEO, will be presenting at the Dry Horizons Symposium (co-sponsored by Ora, Inc.) on Friday May 3rd. His topic will be the company's innovative dry eye disease program, currently in a Phase 3 trial. On Saturday, May 4th he will be presenting the company's latest pre-clinical results in retinitis pigmentosa and in exudative retinal indications at the OIS Retina Meeting. Both of these meetings will be held at the Four Seasons Hotel in Seattle, Washington.

Key Points:

Eric Schlumpf, Stuart Therapeutics' President and CEO, will be presenting at the Dry Horizons Symposium (co-sponsored by Ora, Inc.) on Friday May 3rd.
His topic will be the company's innovative dry eye disease program, currently in a Phase 3 trial.
On Saturday, May 4th he will be presenting the company's latest pre-clinical results in retinitis pigmentosa and in exudative retinal indications at the OIS Retina Meeting.
Members of Stuart Therapeutics' R&D team also co-authored a poster presentation that is being presented by researchers from the University of Rochester at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, which will take place from May 5-9, 2024, in Seattle.

Airdoc Technology (02251.HK) achieved remarkable success in 2023, accelerating its commercialization in an unparalleled way

Retrieved on:

onsdag, april 10, 2024

In 2023, Airdoc Technology significantly accelerated its commercialization，while most of its peers were still in the experimental stage or early stages of commercialization.

Key Points:

In 2023, Airdoc Technology significantly accelerated its commercialization，while most of its peers were still in the experimental stage or early stages of commercialization.
2) health risk assessment solutions, covering 55 types of lesions, providing chronic disease management and health assessments for healthcare industry.
Airdoc Technology practices the use of AI technology to assist in the prevention and control of myopia among teenagers and the development of eye health.
In July 2023, Airdoc Technology participated in the formulation of the "Expert Consensus on Assessing the Risk of Cardiovascular Diseases Using Artificial Intelligence Technology Based on Fundus Images."

Airdoc Technology Unveils 2023 Financial Highlights, Revenue by 79%, Serving 6.83 Million cases

Retrieved on:

onsdag, april 10, 2024

Airdoc Technology Unveils 2023 Financial Highlights, Revenue by 79%, Serving 6.83 Million cases

Key Points:

Airdoc Technology Unveils 2023 Financial Highlights, Revenue by 79%, Serving 6.83 Million cases
On March 27, medical artificial intelligence company Airdoc Technology (2251.
In 2023, through our SaMDs and health risk assessment solutions, we serviced a total of 6.83 million cases and identified 31,459 significant positive cases.
In 2023, Airdoc Medical broadened its reach to include hospitals, grassroots medical institutions such as community clinics, and health examination centers.
In June 2023, Airdoc, in collaboration with Tsinghua University's Chang Gung Hospital, developed and validated a new deep learning-based neovascular segmentation model.